Chen et al reported on the combined application of rAd-p53 and chemotherapy in patients with gastric cancer, indicating that rAd-p53 alone or in combination with oxaliplatin inhibited gastric cancer cell growth and enhanced the tumor sensitivity to oxaliplatin. Here, TP53 is linked to gastric cancer.